Social Psychiatry and Psychiatric Epidemiology

, Volume 49, Issue 7, pp 1063–1070 | Cite as

Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China

  • Somaia MohamedEmail author
  • Robert Rosenheck
  • Hongbo He
  • Ning Yuping
Original Paper



The impact of culture on insight on illness and attitudes towards medication among patients with schizophrenia has not been well studied. We compared inpatients in the US and in China (a culture that numerous studies have shown heavily stigmatizes mental illness and psychosis), on measures of insight and acceptance of medication, controlling for overall severity of schizophrenia symptoms.


Clinical antipsychotic treatment for intervention effectiveness (CATIE) was a large study of pharmacotherapy of people with schizophrenia across the US. Insight was measured using the insight and treatment attitudes questionnaire (ITAQ) and attitudes towards medication by the drug attitude inventory (DAI) and symptoms of schizophrenia by the Positive and Negative Syndrome Scale (PANSS). These measures were applied to a sample of hospitalized patients diagnosed with schizophrenia at the Guangzhou Psychiatric hospital, the largest psychiatric hospital in Southern China. Mean ITAQ and DAI scores, net of total schizophrenia symptoms and other differences were compared at the time of admission using analysis of covariance.


Both insight and favourable attitudes towards medication were significantly and substantially lower in the sample from Guangzhou on bivariate analysis even after adjusting for severity of overall schizophrenia symptoms on the PANSS.


Inpatients in China had far lower scores on measures of insight and acceptance of their need for and benefits of medication, controlling for overall severity of schizophrenia symptoms, suggesting a significant impact of Chinese culture which is presumed to more heavily stigmatize mental illness and especially psychosis, although other explanations can not be ruled out.


Schizophrenia Insight Medication attitude Social functioning Quality of life 


  1. 1.
    Carpenter WT et al (1978) Signs and symptoms as predictors of outcome: a report from the International Pilot Study of Schizophrenia. Am J Psychiatry 135(8):940–944PubMedGoogle Scholar
  2. 2.
    Wilson WH, Ban TA, Guy W (1986) Flexible system criteria in chronic schizophrenia. Compr Psychiatry 27(3):259–265PubMedCrossRefGoogle Scholar
  3. 3.
    Heinrichs DW, Cohen BP, Carpenter WT Jr (1985) Early insight and the management of schizophrenic decompensation. J Nerv Ment Dis 173(3):133–138PubMedCrossRefGoogle Scholar
  4. 4.
    Rosen K, Garety P (2005) Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes. Schizophr Bull 31(3):735–750PubMedCrossRefGoogle Scholar
  5. 5.
    Schwartz RC, Cohen BN, Grubaugh A (1997) Does insight affect long-term impatient treatment outcome in chronic schizophrenia? Compr Psychiatry 38(5):283–288Google Scholar
  6. 6.
    Smith CM, Barzman D, Pristach CA (1997) Effect of patient and family insight on compliance of schizophrenic patients. J Clin Pharmacol 37(2):147–154Google Scholar
  7. 7.
    Osatuke K et al (2008) Insight in schizophrenia: a review of etiological models and supporting research. Compr Psychiatry 49(1):70–77PubMedCrossRefGoogle Scholar
  8. 8.
    David AS (1990) Insight and psychosis. Br J Psychiatry 156:798–808PubMedCrossRefGoogle Scholar
  9. 9.
    Hsiao FH et al (2006) Cultural attribution of mental health suffering in Chinese societies: the views of Chinese patients with mental illness and their caregivers. J Clin Nurs 15(8):998–1006PubMedCrossRefGoogle Scholar
  10. 10.
    Lauber C, Rossler W (2007) Stigma towards people with mental illness in developing countries in Asia. Int Rev Psychiatry 19(2):157–178PubMedCrossRefGoogle Scholar
  11. 11.
    Lam CS et al (2010) Chinese lay theory and mental illness stigma: implications for research and practices. J Rehabil 76:35–40Google Scholar
  12. 12.
    Mellor D et al (2012) Stigma toward mental illness: a cross-cultural comparison of Taiwanese, Chinese immigrants to Australia and Anglo-Australians. J Cross-Cult PsycholGoogle Scholar
  13. 13.
    Yang LH et al (2007) Culture and stigma: adding moral experience to stigma theory. Soc Sci Med 64(7):1524–1535PubMedCrossRefGoogle Scholar
  14. 14.
    Yang LH (2007) Application of mental illness stigma theory to Chinese societies: synthesis and new directions. Singapore Med J 48(11):977–985PubMedGoogle Scholar
  15. 15.
    Yang LH et al (2013) Culture, threat, and mental illness stigma: identifying culture-specific threat among Chinese-American groups. Soc Sci Med 88:56–67PubMedCrossRefGoogle Scholar
  16. 16.
    Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276PubMedCrossRefGoogle Scholar
  17. 17.
    Aggarwal NK et al (2011) Comparing the PANSS in Chinese and American inpatients: cross-cultural psychiatric analyses of instrument translation and implementation. Schizophr Res 132(2–3):146–152PubMedCrossRefGoogle Scholar
  18. 18.
    Aggarwal NK et al (2012) Rater evaluations for psychiatric instruments and cultural differences: the positive and negative syndrome scale in China and the United States. J Nerv Ment Dis 200(9):814–820PubMedCrossRefGoogle Scholar
  19. 19.
    Lieberman JA et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209–1223PubMedCrossRefGoogle Scholar
  20. 20.
    Stroup TS et al (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29(1):15–31PubMedCrossRefGoogle Scholar
  21. 21.
    First M. B et al (1995) Structured clinical interview for DSM-IV (SCID-I) (user’s guide and interview) research version. Biometrics Research Institute, New York State Psychiatric Institute, New YorkGoogle Scholar
  22. 22.
    McEvoy JP et al (1989) Insight in schizophrenia. Its relationship to acute psychopathology. J Nerv Ment Dis 177(1):43–47PubMedCrossRefGoogle Scholar
  23. 23.
    Hogan TP, Awad AG, Eastwood R (1983) A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13(1):177–183PubMedCrossRefGoogle Scholar
  24. 24.
    He Y, Zhang M (2000) The Chinese norm and factor analysis of PANSS. Chinese J Clin Psychol 2 Google Scholar
  25. 25.
    Zhang J et al (1994) Clinical trial of insight and treatment attitude questionnaire (Zi zhi li yu zhi liao tai du wen juan de lin chuang shi yong). Shandong Arch Psychiatry [Shan dong jing shen wei sheng] 4:10–12Google Scholar
  26. 26.
    Mohamed S et al (1999) Insight in schizophrenia: its relationship to measures of executive functions. J Nerv Ment Dis 187(9):525–531PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Somaia Mohamed
    • 1
    Email author
  • Robert Rosenheck
    • 1
  • Hongbo He
    • 2
  • Ning Yuping
    • 2
  1. 1.Yale University School of MedicineNew HavenUSA
  2. 2.Guangzhou Psychiatric HospitalGuangzhouChina

Personalised recommendations